Advertisement
UK markets open in 5 hours 7 minutes

  • NIKKEI 225

    38,845.73
    +228.63 (+0.59%)
     

  • HANG SENG

    18,995.59
    -200.01 (-1.04%)
     

  • CRUDE OIL

    76.85
    -0.72 (-0.93%)
     

  • GOLD FUTURES

    2,374.60
    -18.30 (-0.76%)
     

  • DOW

    39,671.04
    -201.95 (-0.51%)
     

  • Bitcoin GBP

    54,609.70
    -453.16 (-0.82%)
     

  • CMC Crypto 200

    1,512.15
    -14.27 (-0.93%)
     

  • NASDAQ Composite

    16,801.54
    -31.08 (-0.18%)
     

  • UK FTSE All Share

    4,560.55
    -23.85 (-0.52%)
     
Money:

How to protect your finances during divorce

However you do it divorce will leave you poorer, and you will need to watch your finances carefully

Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

For the quarter ended March 2024, Guardant Health (GH) reported revenue of $168.49 million, up 30.9% over the same period last year. EPS came in at -$0.46, compared to -$1.30 in the year-ago quarter.

The reported revenue represents a surprise of +11.94% over the Zacks Consensus Estimate of $150.51 million. With the consensus EPS estimate being -$0.72, the EPS surprise was +36.11%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Guardant Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total tests performed (clinical & biopharmaceutical customers): 55,350 compared to the 55,493 average estimate based on three analysts.

  • Revenue- Development services and other: $12.26 million versus $12.21 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -20% change.

  • Revenue- Precision oncology testing: $156.23 million versus $138.65 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +37.8% change.

View all Key Company Metrics for Guardant Health here>>>

Shares of Guardant Health have returned -2.5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Guardant Health, Inc. (GH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research